Biofrontera (BFRI) vs Chemomab Therapeutics (CMMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Biofrontera (BFRI) has outperformed Chemomab Therapeutics (CMMB) over the past year, losing 28.4% versus a loss of 53.0%. Over five years, CMMB leads with a -96.6% price change compared with -99.7% for BFRI. Chemomab Therapeutics is the larger company by market cap ($9.6 million vs $9.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BFRI | CMMB |
|---|---|---|
| Share price | $0.53 | $1.19 |
| Market cap | $9.51M | $9.58M |
| 1-day change | -7.02% | +4.39% |
| YTD return | -7.02% | -27.88% |
| 1-year return | -28.38% | -52.96% |
| 5-year return | -99.66% | -96.65% |
| Forward P/E | 1.32 | — |
| EPS (TTM) | $-0.26 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $41.70M | — |
| Revenue growth (YoY) | +11.75% | — |
| Net income (latest FY) | $-10.54M | $-8.99M |
| Operating margin | -27.21% | — |
| Net margin | -25.26% | — |
| 52-week high | $1.66 | $2.99 |
| 52-week low | $0.53 | $0.92 |
| Distance from 52-week high | -68.07% | -60.20% |
| Analyst consensus | none | none |
| Avg. price target upside | +1032.08% | +320.17% |
| Average volume | 429.04K | 102.39K |
| Shares outstanding | 17.95M | 8.05M |
| Employees | 84 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BFRI has outperformed CMMB by 24.6 percentage points over the past year.
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
About Chemomab Therapeutics
CMMB stock →Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations
BFRI vs CMMB FAQ
Which is bigger, Biofrontera or Chemomab Therapeutics?
Chemomab Therapeutics (CMMB) is larger, with a market capitalization of $9.58M compared with $9.51M for Biofrontera (BFRI).
Which stock has performed better over the past year, BFRI or CMMB?
BFRI returned -28.38% over the past 12 months, compared with -52.96% for CMMB (price return, excluding dividends). Past performance does not predict future results.
Are Biofrontera and Chemomab Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.